Now that we have that out of our way
The interim analysis could have taken place as early as the end of last year based on events it did happen early this year. And so the consequence, the impact of that delays is what is taking the estimate for a final analysis to the end of this year beginning of next year, but we have not seen any OS data and we can't speculate on what that means we are following the events.Maybe we can now pivot two biomarkers so TMB looks like a very interesting biomarker that's an important step forward, perhaps you can talk about the TMB marker versus the PD L1 biomarker. And why you feel TMB could be a more useful biomarker in gauging IO therapy? And if you can also add in the Roche test biomarker which they have been talking about and compare and contrast on.Great question Steve, I wouldn't start by saying, we are talking about really two different things when we talk about TMB Tumor Mutational Burden and the potential for tumor to generate new antigens and make itself very visible to...